Skip to main content
SpringerLink
Log in

The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression

  • Pharmacodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to investigate the relationship between plasma glutamate, glutamine and γ-aminobutyric acid (GABA) levels in female patients with major depression treated with S-citalopram or fluoxetine.

Methods

The patients were assigned into S-citalopram (10 mg/day) or fluoxetine (20 mg/day) groups (n = 15 per group). The Hamilton and Beck Depression Inventory Scales were performed on all study participants, and blood samples were collected. The same procedures were repeated 10 days following the onset of therapy. Fifteen female healthy volunteers were also included in the study for the evaluation of normal plasma levels.

Results

The plasma GABA levels of the healthy volunteers were higher whereas those for glutamate and glutamine were lower than the day zero samples of the patients. An increase in plasma GABA levels and a decrease in glutamate and glutamine levels were observed on the 10th day of treatment. No difference was detected between the drug treatments.

Conclusion

Our findings may suggest that GABA, glutamate and glutamine play a role in depression and that plasma GABA may be used as a biomarker for treatment control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

CSF:

Cerebrospinal fluid

GABA:

γ-Aminobutyric acid

Glu:

Glutamate

Gln:

Glutamine

SSRI:

Selective serotonin reuptake inhibitors

References

  1. Klerman GL, Weissman MM (1988) The changing epidemiology of depression. Clin Chem 34:807–812

    PubMed  CAS  Google Scholar 

  2. Angst J, Preisig M (1995) Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from (1959) to 1985. Arch Neuro Psychiatr 146:5–16

    CAS  Google Scholar 

  3. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509–522

    PubMed  CAS  Google Scholar 

  4. Slattery DA, Hudson AL, Nutt DJ (2004) Invited review: The evolution of antidepressant mechanisms. Fundam Clin Pharmacol 18:1–21

    Article  PubMed  CAS  Google Scholar 

  5. Bloom F, Iversen LL (1971) Localising [3H]GABA in nerve terminals of rat cerebral cortex by electromicroscopic autoradiography. Nature 229:628–630

    Article  PubMed  CAS  Google Scholar 

  6. Young AB, Chu D (1990) Distrubition of GABAA and GABAB receptors in mammalian brain: potential targets for drug development. Drug Dev Res 21:161–167

    Article  CAS  Google Scholar 

  7. Zhou FM, Hablitz JJ (1999) Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. J Neurophysiol 82:2989–2999

    PubMed  CAS  Google Scholar 

  8. Feng J, Cai X, Zhao J, Yan Z (2001) Serotonin receptors modulate GABAA receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. J Neurosci 21:6502–6511

    PubMed  CAS  Google Scholar 

  9. Cai X, Flores-Hernandez J, Feng J, Yan Z (2002) Activity-dependent bi-directional regulation of GABAA receptor channels by serotonin 5-HT4 receptors in pyramidal neurons of the prefrontal cortex. J Physiol 540:743–759

    Article  PubMed  CAS  Google Scholar 

  10. Yan Z (2002) Regulation of GABAA receptor channels by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications. Mol Neurobiol 26:203–216

    Article  PubMed  CAS  Google Scholar 

  11. Brambilla P, Perez J, Barale F, Shettini G, Soares JC (2003) GABAergic dysfunction in mood disorders. Mol Psychiatry 8:721–737

    Article  PubMed  CAS  Google Scholar 

  12. Fiske E, Gronli J, Bjorvatn B, Ursin R, Portas CM (2006) The effect of GABA(A) antagonist bicuculline on dorsal raphe nucleus and frontal cortex extracellular seroton: a window on SWS and REM sleep modulation. Pharmacol Biochem Behav 83:314–321

    Article  PubMed  CAS  Google Scholar 

  13. Serrats J, Artigas F, Mengod G, Cortes R (2003) GABAB receptor mRNA in the raphe nuclei: co-expression with serotonin transporter and glutamic acid decarboxylase. J Neurochem 4:743–752

    Article  Google Scholar 

  14. Tao R, Ma Z, Auerbach SB (1996) Differential regulation of 5-hydroxytryptamine release by GABAA and GABAB receptors in midbrain raphe nuclei and forebrain of rats. Br J Pharmacol 119:1375–1384

    PubMed  CAS  Google Scholar 

  15. Petty F (1995) GABA and mood disorders: a brief review and hypothesis. J Affect Disord 34:275–281

    Article  PubMed  CAS  Google Scholar 

  16. Freund TF (1992) GABAergic septal and serotonergic median raphe afferents preferentially innervate inhibitory interneurons in the hippocampus and dentate gyrus. Epilepsy Res 7:79–91

    CAS  Google Scholar 

  17. Freund TF, Gulyas AI, Acsady L, Gorcs T, Toth K (1990) Serotonergic control of the hippocampus via local inhibitory interneurons. Proc Natl Acad Sci USA 87:8501–8505

    Article  PubMed  CAS  Google Scholar 

  18. Halasky K, Miettinen R, Szabat E, Freund TF (1992) GABAergic interneurons are the major postsynaptic targets of median raphe afferents in the rat dentate gyrus. Eur J Neurosci 4:144–153

    Article  Google Scholar 

  19. Gören MZ, Kucukibrahimoglu E, Berkman K, Terzioglu B (2007) Fluoxetine Partly Exerts Its Actions Through GABA: A Neurochemical Evidence. Neurochem Res 32(9):1559–1565

    Article  PubMed  Google Scholar 

  20. Rowley HL, Martin KF, Marsden CA (1995) Determination of in vivo amino acid neurotransmitters by high-performance liquid chromatography with o-phythalaldehyde-sulphite derivatisation. J Neurosci Methods 57:93–99

    Article  PubMed  CAS  Google Scholar 

  21. Smith S, Sharp T (1994) Measurement of GABA in rat brain microdialysates using o-phthaldialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection. J Chromatogr B 652:228–233

    Article  CAS  Google Scholar 

  22. Löscher W, Frey H-H (1982) Transport of GABA at the Blood-CSF Interface. J Neurochem 38(4):1072–1079

    Article  PubMed  Google Scholar 

  23. Vignolo L, Cupello A, Mainardi P, Rapallino MV, Patrone A, Loeb C (1992) Accumulation of labeled gamma-aminobutyric acid into rat brain and brain synaptosomes after i.p. injection. Neurochem Res 17(2):193–199

    Google Scholar 

  24. Petty F, Kramer GL, Gullian CM, Rush AJ (1992) Low plasma GABA levels in male patients with depression. Biol Psychiatry 32:354–363

    Article  PubMed  CAS  Google Scholar 

  25. Sanacora G, Mason GF, Rothman DL, Krystal JH (2002) Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159:663–665

    Article  PubMed  Google Scholar 

  26. Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB (2003) Increased cortical GABA concentrations in depressed patients receiving ETC. Am J Psychiatry 160:577–579

    Article  PubMed  Google Scholar 

  27. Benes FM, Sorensen I, Vincent SL, Bird ED, Sathi M (1992) Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. Cereb Cortex 2:503–512

    Article  PubMed  CAS  Google Scholar 

  28. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998–1007

    PubMed  CAS  Google Scholar 

  29. Sanacora G, Guegorguieva R (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 7:705–713

    Article  Google Scholar 

  30. Kendell SF, Krystal JH, Sanacora G (2005) GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 9:153–168

    Article  PubMed  CAS  Google Scholar 

  31. Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 11:1310–1316

    Article  Google Scholar 

  32. Novak G, Trullas R, Layer RT, Skolnick P, Paul IA (1993) Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 65:1380–1386

    Google Scholar 

  33. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P (1994) Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 69:95–102

    Google Scholar 

  34. Nonaka S, Hough CJ, Chuang DM (1998) Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 95:2642–2647

    Article  PubMed  CAS  Google Scholar 

  35. Popik P, Wrobel M, Nowak G (2000) Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence. Neuropharmacology 39:2278–2287

    Article  PubMed  CAS  Google Scholar 

  36. Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:1–10

    Article  PubMed  CAS  Google Scholar 

  37. Layer RT, Popik P, Olds T, Skolnick P (1995) Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol Biochem Behav 52:621–627

    Article  PubMed  CAS  Google Scholar 

  38. Przegalinski E, Tatarczynska E, Chojnacka-Wojcik E (2000) The influence of the benzodiyazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology 39:1858–1864

    Article  PubMed  CAS  Google Scholar 

  39. Berman RB, Cappiello A, Anand A (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 4:351–354

    Article  Google Scholar 

  40. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864

    Article  PubMed  CAS  Google Scholar 

  41. Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR, Kawahara R (2006) Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Progr Neuro-Psychopharmacol Biol Psychiatry 6:1155–1158

    Article  Google Scholar 

  42. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW (2000) Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 7:586–593

    Google Scholar 

  43. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F (2000) Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47:305–313

    Article  PubMed  CAS  Google Scholar 

  44. Pfleiderer B, Nikolaus M, Andreas E, Ohrmann P, Hohmann U, Wolgasta M, Fiebich M, Arolt V, Heindel W (2003) Effective electroconvulsive therapy reverses glutamateyglutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res Neuroimaging 122:185–192

    Article  CAS  Google Scholar 

  45. Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B (2003) Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol Med 33:1277–1284

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was sponsored with grants received from “Marmara University Scientific Research Projects Commission” (BAPKO; SAG-TUS290906-0204 and SAG-A-030408-0071).

Author information

Authors and Affiliations

  1. Department of Pharmacology and Clinical Pharmacology, Marmara University School of Medicine, Haydarpaşa, Istanbul, 34668, Turkey

    Esra Küçükibrahimoğlu & M. Zafer Gören

  2. Haydarpaşa State Reference Hospital (Haydarpaşa Numune Hastanesi), Psychiatry Clinics, Turkish Ministry of Health, Haydarpaşa, Istanbul, 34668, Turkey

    Melek Z. Saygın, Mecit Çalışkan, Okan K. Kaplan & Cüneyt Ünsal

Authors
  1. Esra Küçükibrahimoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melek Z. Saygın
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mecit Çalışkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Okan K. Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cüneyt Ünsal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Zafer Gören
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Zafer Gören.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Küçükibrahimoğlu, E., Saygın, M.Z., Çalışkan, M. et al. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur J Clin Pharmacol 65, 571–577 (2009). https://doi.org/10.1007/s00228-009-0650-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-009-0650-7

Keywords

Search

Navigation